Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study
Frontiers in Pharmacology · 02.11.2026 · 17
DOI: 10.3389/fphar.2026.1938738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.11.2026. Verfasst von Yang Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Coronary microvascular dysfunction (CMD or CMVD), a major subtype of angina with non-obstructive coronary arteries, affects a substantial proportion of patients and represents an important unmet clinical need, particularly in China. Studies evaluating comparative treatment efficacy in angina populations, especially across CMVD and non-CMVD, remain limited.
Objective
To assess the efficacy of different therapeutic regimens (nicorandil vs. non-nicorandil treatment) among angina pectoris patients with CMVD.
Methods
We conducted a retrospective analysis of baseline and follow-up data from nine centres of the GREAT study, including patients with angina from nine hospitals in China treated with nicorandil or non-nicorandil regimens. Patients with and without CMVD (coronary angiography-derived index of microvascular resistance [caIMR], ≥25 vs. < 25) were included, and post-treatment differences in Seattle Angina Questionnaire (SAQ) scores were compared between groups.
Results
A total of 1,259 patients with angina were included in this study. Among them, 429 patients had CMVD (caIMR ≥25), comprising 170 in the nicorandil group and 259 in the non-nicorandil group, while 830 patients did not have CMVD (nicorandil group, 319; non-nicorandil group, 511). After propensity score matching, the mean SAQ summary score (SAQ-SS) improvement in patients with CMVD, was greater in the nicorandil group than in the non-nicorandil group (mean change: 16.80 vs. 12.60, P = 0.044). Among patients without CMVD, nicorandil therapy resulted in significantly greater SAQ-SS improvement at respective timepoints (3 months: 15.68 vs. 12.15, P = 0.005; 6 months: 18.70 vs. 14.44, P < 0.001; 9 months: 18.11 vs. 15.07, P = 0.008).
Conclusion
Nicorandil-based regimens may be associated with greater improvement in health status among angina patients with CMVD compared with non-nicorandil treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, Jiangsu, China.
- Department of Cardiology, Ruyang People's Hospital, Henan, China.
- Department of Cardiology, Beijing Miyun Hospital, Peking University First Hospital, Beijing, China.
- Department of Cardiology, Beijing Daxing District People's Hospital, Beijing, China.
- Department of Cardiology, Beijing Changping District Hospital, Beijing, China.
Zitieren
APA
Zhang, Y., Xu, S., Wu, L., Liu, Y., Du, X., Cheng, G., Sun, L., Wei, Y., Liu, W., Miao, L., Zhang, Q., Ma, C., & Zeng, Y. (2026). Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1938738
Vancouver
Zhang Y, Xu S, Wu L, Liu Y, Du X, Cheng G, et al. Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1938738
BibTeX
@article{Zhang2026,
author = {Zhang, Yang and Xu, Su'e and Wu, Litao and Liu, Yajuan and Du, Xin and Cheng, Guojie and Sun, Liling and Wei, Ying and Liu, Wei and Miao, Lifu and Zhang, Qihua and Ma, Changsheng and Zeng, Yong},
title = {Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1938738}
}
EUVIMED